

Application No.: 09/975,136

2


Docket No.: 524022000108

FAX RECEIVED
AUG 19 2003
GROUP 1600

AMENDMENTS TO THE CLAIMS

Claims 1-4 (Canceled).

Claim 5 (Currently Amended): A method for treating or preventing a disease or disorder caused by *Helicobacter pylori* (*H. pylori*) infection, which method comprises administering, to a subject ~~to~~ for which such treatment or prevention is needed or desirable, an effective amount of ~~the a~~ a compound ~~of claim 1~~ having the following formula I:



wherein n is 0 or 1, and R is selected from the group consisting of C₁₋₁₀ alkyl, C₆₋₁₀ aryl and




and wherein when n is 0, R is not C₆₋₁₀ aryl, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

Claim 6 (Original): The method of claim 5, wherein the subject is a mammal.


Claim 7 (Original): The method of claim 6, wherein the mammal is a human.

Claim 8 (Previously Amended: The method of claim 5, which comprises administering a compound having the following formula II:



or a pharmaceutically acceptable salt thereof, to the subject.

Claim 9 (Previously Amended): The method of claim 5, which comprises administering a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, having the following formula I:



sd-160861

Application No.: 09/975,136

3

Docket No.: 524022000100

wherein n is 0 or 1, and R is selected from the group consisting of C_{1-10} alkyl, C_{6-10} aryl and



and wherein when n is 0, R is not C_{6-10} aryl to the subject.

Claim 10 (Currently Amended): The method of claim 5, wherein the disease or disorder caused by *H. pylori* infection to be treated or prevented is chronic gastritis, gastroduodenal ulcer, adenocarcinoma of the distal stomach, gastric lymphoma or gastric cancer.

Claim 11 (Original): The method of claim 5, wherein the subject is treated without administering an anti-*H. pylori* agent.


Claim 12 (Currently Amended): The method of claim 11, wherein the anti-*H. pylori* agent is a proton-pump inhibitor (PPI), metronidazole, clarithromycin or amoxicillin.

Claim 13 (Original): The method of claim 5, wherein the *H. pylori* is a resistant strain induced by PPI, metronidazole, clarithromycin or amoxicillin treatment.

Claim 14 (Original): The method of claim 5, wherein the compound or a pharmaceutically acceptable salt thereof is administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, oral administration, or topical administration.

Claim 15 (Previously Amended): The method of claim 5, which further comprises a step of diagnosis or prognosis of *H. pylori* infection in the subject.

Claim 16 (Currently Amended): A composition, which composition comprises the a compound of claim 1, having the following formula I:




sd-160861

Application No.: 09/975,136

4

Docket No.: 524022000100

wherein n is 0 or 1, and R is selected from the group consisting of C₁₋₁₀ alkyl, C₆₋₁₀ aryl and



and wherein when n is 0, R is not C₆₋₁₀ aryl, or a pharmaceutically acceptable salt thereof,
and an anti-*H. pylori* agent.

Claim 17 (Previously Amended): The composition of claim 16, wherein the anti-*H. pylori* agent is PPI, metronidazole, clarithromycin or amoxicillin.


Claim 18 (Currently Amended): A method for treating or preventing a disease or disorder caused by *H. pylori* infection, which method comprises administering, to a subject to for which such treatment or prevention is needed or desirable, an effective amount of the composition of claim 16, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

Claim 19 (Canceled).

Claim 20 (Previously Amended): A kit, which kit comprises the composition of claim 16, and an instruction for using said composition in treating or preventing a disease or disorder caused by *H. pylori* infection.

Claim 21 (Canceled).

Claim 22 (New): A compound, which has the following formula II:



or a pharmaceutically acceptable salt thereof.

sd-160861

Application No.: 09/975,136

5

Docket No.: 524022000100

Claim 23 (New): A pharmaceutical composition, which composition comprises the compound of claim 22 and a pharmaceutically acceptable carrier or excipient.

Claim 24 (New): A kit, which kit comprises the compound of claim 22, or a pharmaceutically acceptable salt thereof, and an instruction for using said compound or pharmaceutically acceptable salt in treating or preventing a disease or disorder caused by *H. pylori* infection.

sd-160861